Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase NA 1

Status

Completed 5Recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6Other hematologic neoplasm 1

Conditions

Multiple Myeloma 420Lymphoma, Large B-Cell, Diffuse 93Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 79Recurrence 68Lymphoma 60Neoplasms, Plasma Cell 57Lymphoma, Mantle-Cell 56Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Leukemia, Myeloid, Acute 34Leukemia 32Lymphoma, B-Cell 24Neoplasms 23Myelodysplastic Syndromes 23Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Smoldering Multiple Myeloma 17Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Hematologic Diseases 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Prostatic Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Lymphoma, Large-Cell, Anaplastic 9Leukemia, Myelomonocytic, Chronic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

Dexamethasone 21Calcium Dobesilate 10Melphalan 9Bortezomib 8Cyclophosphamide 7Lenalidomide 6pomalidomide 4miridesap 3daratumumab 3venetoclax 2ixazomib 2belantamab mafodotin 2Thalidomide 2Doxycycline 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2selinexor 1pegfilgrastim 1isatuximab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1birtamimab 1auricularum 1Vinorelbine 1Technetium Tc 99m Pyrophosphate 1Technetium 1Tacrolimus 1Surveys and Questionnaires 1Pharmaceutical Preparations 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Amyloidosis × Lenalidomide × Clear all
NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

University of Alabama at Birmingham

Phase 2 Recruiting
40 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT03959358 2023-07-24

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

University Health Network, Toronto

Phase 2 Completed
10 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

NCT00981708 2021-04-30

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

University of Athens

Phase 1/2 Completed
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Recurrence

NCT01194791 2017-04-25

LENDEXAL

PETHEMA Foundation

Phase 2 Completed
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT00890552 2017-03-22

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Stanford University

Phase NA Completed
25 enrolled 12 charts
Other hematologic neoplasmPlasma cell

Amyloidosis, Leukemia

NCT00621400 2011-05-10

Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis

Nantes University Hospital

Phase 1/2 Completed
27 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡